Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

JOHNSON & JOHNSON INVESTIGATION UPDATE by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Johnson & Johnson - JNJ

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/16/2019 | 10:51pm EDT

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Johnson & Johnson (“J&J”) (NYSE: JNJ).

The Company has been embroiled in significant litigation by over 11,000 consumers claiming that its iconic talc powder products contained asbestos that caused cancer. Some cases have resulted in massive verdicts against J&J including a $117 million award by one New Jersey jury in April 2018 and a $4.7 billion award in Missouri to 22 plaintiffs in July 2018. On July 12, 2019, news sources reported that the Company was under investigation by the U.S. Justice Department regarding whether it lied about the possible cancer risks from its talcum powder.

Recently, on July 29, 2019, the Company disclosed that it had received a civil investigative demand from the Federal Trade Commission relating to possible antitrust law violations by the Company in marketing its blockbuster rheumatoid arthritis drug, Remicade.

The Company has been exposed to significant financial losses as well as a securities class action lawsuit for failing to disclose material information to investors, violating federal securities laws, which is ongoing.

KSF’s investigation is focusing on whether J&J’s officers and/or directors breached their fiduciary duties to its shareholders or otherwise violated state or federal laws.

If you have information that would assist KSF in its investigation, or have been a long-term holder of J&J shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nyse-jnj/ to learn more.

About Kahn Swick & Foti, LLC

KSF, whose partners include Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.

To learn more about KSF, you may visit www.ksfcounsel.com.


© Business Wire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
09/19JOHNSON & JOHNSON : Janssen to Highlight Depth of Prostate Cancer and Solid Tumo..
PU
09/19JOHNSON & JOHNSON : U.S. FDA Approves Supplemental New Drug Application (sNDA) f..
PU
09/18JOHNSON & JOHNSON : to Host Investor Conference Call on Third Quarter Results
PR
09/18THE LATEST : J&J company says it will fight WVa mesh lawsuit
AQ
09/18JOHNSON & JOHNSON : - U.S. FDA Approves Supplemental New Drug Application for ER..
AQ
09/17JOHNSON & JOHNSON : Janssen to Highlight Depth of Prostate Cancer and Solid Tumo..
PU
09/17JOHNSON & JOHNSON : Janssen Submits Application to U.S. FDA Seeking First-in-Cla..
AQ
09/16JOHNSON & JOHNSON : Janssen Submits Application to U.S. FDA Seeking First-in-Cla..
PU
09/16JOHNSON & JOHNSON : Vision Introduces TECNIS Synergy™ IOL, a Continuous-Ra..
PU
09/16JOHNSON & JOHNSON : - New DARZALEX Data from GRIFFIN Study Show High Response Ra..
AQ
More news
Financials (USD)
Sales 2019 81 612 M
EBIT 2019 25 394 M
Net income 2019 19 218 M
Debt 2019 5 560 M
Yield 2019 2,85%
P/E ratio 2019 18,9x
P/E ratio 2020 16,9x
EV / Sales2019 4,33x
EV / Sales2020 4,07x
Capitalization 347 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 21
Average target price 148,75  $
Last Close Price 131,65  $
Spread / Highest target 28,4%
Spread / Average Target 13,0%
Spread / Lowest Target -5,81%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Charles O. Prince Independent Director
William David Perez Independent Director
Anne M. Mulcahy Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON0.82%347 446
ROCHE HOLDING LTD.16.27%245 289
MERCK AND COMPANY11.45%218 042
PFIZER-15.95%202 934
NOVARTIS15.60%199 009
NOVO NORDISK AS17.30%124 981